Alternatives to antibiotics—a pipeline portfolio review

Articles citing Alternatives to antibiotics—a pipeline portfolio review

Title / Author	Year
Antimicrobial peptides: an emerging category of therapeutic agents M Mahlapuu, J Håkansson, L Ringstad, C Björn Frontiers in cellular and infection microbiology 6, 194	2016
Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges D Wong, TB Nielsen, RA Bonomo, P Pantapalangkoor, B Luna, ... Clinical microbiology reviews 30 (1), 409-447	2017
Antimicrobial photodynamic inactivation: a bright new technique to kill resistant microbes MR Hamblin Current opinion in microbiology 33, 67-73	2016
Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance SW Dickey, GYC Cheung, M Otto Nature Reviews Drug Discovery 16 (7), 457	2017
Antibiotics in the clinical pipeline at the end of 2015 MS Butler, MAT Blaskovich, MA Cooper The Journal of antibiotics 70 (1), 3-24	2017
Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis World Health Organization World Health Organization	2017
Achieving global targets for antimicrobial resistance R Laxminarayan, D Sridhar, M Blaser, M Wang, M Woolhouse Science 353 (6302), 874-875	2016
Natural products as a source for novel antibiotics MG Moloney Trends in Pharmacological Sciences 37 (8), 689-701	2016
Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen DR Roach, CY Leung, M Henry, E Morello, D Singh, JP Di Santo, ... Cell host & microbe 22 (1), 38-47. e4	2017
Formulation, stabilisation and encapsulation of bacteriophage for phage therapy DJ Malik, IJ Sokolov, GK Vinner, F Mancuso, S Cinquerrui, ... Advances in colloid and interface science 249, 100-133	2017
Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach M Bassetti, G Poulakou, E Ruppe, E Bouza, SJ Van Hal, A Brink Intensive care medicine 43 (10), 1464-1475	2017
Antimicrobial photodynamic therapy–what we know and what we don’t F Cieplik, D Deng, W Crielaard, W Buchalla, E Hellwig, A Al-Ahmad, ... Critical Reviews in Microbiology 44 (5), 571-589	2018
Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases A Górski, R Międzybrodzki, B Weber-Dąbrowska, W Fortuna, S Letkiewicz, ... Frontiers in microbiology 7, 1515	2016
Beyond antibiotics: new therapeutic approaches for bacterial infections AR Hauser, J Mecsas, DT Moir Clinical Infectious Diseases 63 (1), 89-95	2016
Advances in development of antimicrobial peptidomimetics as potential drugs N Molchanova, PR Hansen, H Franzyk Molecules 22 (9), 1430	2017
Transmission of the gut microbiota: spreading of health HP Browne, BA Neville, SC Forster, TD Lawley Nature Reviews Microbiology 15 (9), 531-543	2017
Considerations and caveats in anti-virulence drug development D Maura, AE Ballok, LG Rahme Current opinion in microbiology 33, 41-46	2016
The one health concept: 10 years old and a long road ahead D Destoumieux-Garzón, P Mavingui, G Boëtsch, J Boissier, F Darriet, ... Frontiers in veterinary science 5, 14	2018
Pseudomonas predators: understanding and exploiting phage–host interactions J De Smet, H Hendrix, BG Blasdel, K Danis-Wlodarczyk, R Lavigne Nature Reviews Microbiology 15 (9), 517	2017
Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities M Asif, IA Alvi, SU Rehman Infection and drug resistance 11, 1249	2018

1 - 20

Dates and citation counts are estimated and are determined automatically by a computer program.